The Effects of Real-World Evidence on the Treatment of HER2+ mBC - Episode 13

Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC

November 16, 2023

Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Evolution of Advanced HER2+ Breast Cancer Management

EP. 2: Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)

EP. 3: The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC

EP. 4: Approaches to Sequencing Therapies for HER2+ mBC

EP. 5: Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC

EP. 6: Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC

EP. 7: Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment

EP. 8: Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)

EP. 9: Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

EP. 10: Novel Therapies Under Investigation for HER2+ mBC

EP. 11: Treatment Sequencing Approaches for Patients With HER2+ mBC

EP. 12: French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC

Now Viewing

EP. 13: Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC

EP. 14: Treatment Approaches for Patients With HER2+ mBC and Brain Metastases

EP. 15: Novel Treatment Approaches Under Investigation for HER2+ mBC